What's new

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Mar 17, 2025 - 15:10
 0
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024
Read More

Tags:

Previous Article

AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal

Next Article

PepsiCo to acquire poppi

Related Posts

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025  0

Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab, Date of authorisation: 19/04/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025  0

Human medicines European public assessment report (EPAR): Daptomycin Hospira, daptomycin, Date of authorisation: 22/03/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 17, 2025  0